New Hepatitis B Drug Cures 1 in 5 Patients in Trials

For the first time, doctors have a real shot at curing hepatitis B in a meaningful number of patients.

GSK's experimental drug bepirovirsen helped one in five people with chronic hepatitis B achieve a functional cure in Phase 3 clinical trials. That might sound modest, but it's revolutionary compared to today's standard treatments, which cure only 1% to 3% of patients.

The results come from two separate trials where 20% and 19% of patients respectively reached functional cure status. Not a single person taking the placebo achieved the same result, making the difference crystal clear.

Between 250 million and 300 million people worldwide live with chronic hepatitis B infections. The virus silently damages the liver over years, often leading to cirrhosis and liver cancer. Every year, hepatitis B kills roughly one million people.

Current medications, called nucleoside analogues, can suppress the virus but rarely eliminate it. Patients typically need lifelong treatment to keep the infection under control. A functional cure means the virus stays suppressed without ongoing medication, giving people their lives back.

The treatment works differently than existing options, targeting the virus through a new mechanism. While GSK hasn't publicly released all the details, the Phase 3 success suggests the drug could receive regulatory approval within the next few years.

The Ripple Effect

The impact extends far beyond individual patients. Hepatitis B disproportionately affects people in lower-income countries, particularly in Asia and Africa where the virus spreads from mother to child during birth.

A more effective cure could transform public health in these regions. Fewer chronic infections mean fewer cases of liver cancer and cirrhosis, reducing the burden on already stretched healthcare systems.

The pharmaceutical industry has largely overlooked hepatitis B in recent decades, focusing instead on hepatitis C, which has already seen multiple cure breakthroughs. This new data proves that hepatitis B doesn't have to remain the "forgotten hepatitis" anymore.

Researchers are already talking about combination approaches. Pairing bepirovirsen with other emerging treatments could push cure rates even higher, potentially reaching the majority of patients within a decade.

For the 300 million people waiting for better options, these trials represent the most hopeful news in a generation.